We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-11.26%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$800M
AUM Growth
-$414M
Cap. Flow
-$240M
Cap. Flow %
-29.97%
Top 10 Hldgs %
59.99%
Holding
111
New
25
Increased
21
Reduced
27
Closed
33

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$26.8M
2
MRK icon
Merck
MRK
+$25.8M
3
PFE icon
Pfizer
PFE
+$19.8M
4
ABBV icon
AbbVie
ABBV
+$14.1M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$13.5M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$21.3M
2
VRNT
Verint Systems
VRNT
+$16.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$12.8M
4
VTRS icon
Viatris
VTRS
+$11.3M
5
PTCT icon
PTC Therapeutics
PTCT
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 65.88%
2 Technology 4.53%
3 Consumer Discretionary 1.29%
4 Communication Services 0.33%
5 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
51
Larimar Therapeutics
LRMR
$397M
$2.43M 0.3%
263,464
+234,491
+809% +$3.08M
EOLS icon
52
Evolus
EOLS
$385M
$2.28M 0.29%
550,000
+400,000
+267% +$3.39M
ARYAU
53
DELISTED
ARYA Sciences Acquisiton Corp. Unit
ARYAU
$2.26M 0.28%
200,000
– –
APLT
54
DELISTED
Applied Therapeutics
APLT
$2.22M 0.28%
+67,967
New +$2.75M
PRQR icon
55
ProQR Therapeutics
PRQR
$243M
$1.9M 0.24%
346,148
-458,852
-57% -$3.52M
NEOS
56
DELISTED
Neos Therapeutics, Inc
NEOS
$1.88M 0.24%
2,509,468
-1,021,263
-29% -$1.4M
KALV
57
DELISTED
KalVista Pharmaceuticals
KALV
$1.84M 0.23%
240,140
+92,440
+63% +$1.25M
VRTX icon
58
Vertex Pharmaceuticals
VRTX
$121B
$1.67M 0.21%
+7,000
New +$1.61M
IMVTU
59
DELISTED
Immunovant, Inc. Units
IMVTU
$1.56M 0.2%
94,500
-5,500
-6% -$106K
ARGX icon
60
argenx
ARGX
$53.4B
$1.35M 0.17%
10,265
-6,316
-38% -$924K
GBT
61
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.26M 0.16%
+24,752
New +$1.66M
NERV icon
62
Minerva Neurosciences
NERV
$185M
$1.01M 0.13%
21,045
-85,830
-80% -$5.18M
CYPH
63
Cypherpunk Technologies Inc
CYPH
$62.9M
$948K 0.12%
+60,000
New +$1.16M
DTIL icon
64
Precision BioSciences
DTIL
$180M
$889K 0.11%
4,912
-11,546
-70% -$3.02M
APTX
65
DELISTED
Aptinyx Inc. Common Stock
APTX
$889K 0.11%
+411,666
New +$1.35M
SNDX icon
66
Syndax Pharmaceuticals
SNDX
$1.69B
$747K 0.09%
+68,134
New +$639K
ALNA
67
DELISTED
Allena Pharmaceuticals
ALNA
$643K 0.08%
667,800
-250,000
-27% -$500K
STOK icon
68
Stoke Therapeutics
STOK
$1.8B
$624K 0.08%
27,254
-229,126
-89% -$5.66M
ISEE
69
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$425K 0.05%
123,424
-744,776
-86% -$4.35M
ZYNE
70
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$383K 0.05%
+100,000
New +$465K
CYCN icon
71
Cyclerion Therapeutics
CYCN
$14.9M
$331K 0.04%
+6,249
New +$446K
VIRX
72
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$299K 0.04%
20,623
-40,571
-66% -$881K
IMVT icon
73
Immunovant
IMVT
$7.93B
$296K 0.04%
19,032
-968
-5% -$14.6K
BMY.RT
74
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$190K 0.02%
+50,000
New +$165K
OTLKW
75
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$130K 0.02%
+129,500
New +$15.2K
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2020 Portfolio in Review

As of Q1 2020, Sphera Funds Management held 111 positions worth $800M, down 34% from $1.21B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sphera Funds Management withdrew a net $240M in Q1 2020, closing 33 positions and reducing 27 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $21.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 52% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in AstraZeneca worth $25.5M.

  • Sphera Funds Management's largest Q1 2020 buy was AstraZeneca: 285,000 shares worth $25.5M.
  • Sphera Funds Management added most to Merck in Q1 2020, an estimated $25.8M increase.
  • Sphera Funds Management's biggest Q1 2020 reduction was Johnson & Johnson, cutting an estimated $12.8M.
  • Sphera Funds Management fully exited BioMarin Pharmaceuticals in Q1 2020, selling an estimated $21.3M.
  • Sphera Funds Management's ten largest holdings make up 60% of its $800M portfolio in Q1 2020.
  • Sphera Funds Management opened 25 new positions and closed 33 in Q1 2020.
  • Sphera Funds Management's portfolio value fell 34% quarter-over-quarter to $800M.

Based on Sphera Funds Management's 13F filing for Q1 2020, filed 14 May 2020.